However, anticancer effect and mechanism of fluoxetine in HCC and NSCLC in vivo still needs to be elucidated. In light of these results, we suggest that MV repair surgery should be a priority for NIMR patients.įluoxetine, an antidepressant, has been indicated to elicit anti-cancer response in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) in vitro. In patients with NIMR, MV repair achieves higher survival and leads to fewer complications than surgical MV replacement. Moreover, the rate of re-operation and post-operative MR in the MV repair group was lower than in the MV replacement group.
We found that there were significantly increased risks of mortality associated with replacement of MR. The number of patients in the MV repair group was lower than in the MV replacement group. No significant differences in the rates of pre-operative left ventricle ejection fraction (LVEF) and heart failure were observed between groups. The pooled analysis showed that lower age, less female inclusion and incident of hypertension, significantly higher rates of diabetes and atrial fibrillation in the MV replacement group than MV repair group. The literature search yielded 4834 studies, of which 20 studies, including a total of 21,898 patients with NIMR, were included. This study is registered with PROSPERO, CRD42018089608.
For each study, data on all-cause mortality and incidence of reoperation and operative complications in both groups were used to generate odds ratios (ORs) or hazard ratios (HRs). Studies were eligible for inclusion if they included patients with MR and reported early (30-day or in-hospital) or late all-cause mortality. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched until October, 2020. The aim of this systematic review and meta-analysis was to compare the outcomes, and complications of mitral valve (MV) replacement with surgical MV repair of non-ischemic MR (NIMR) Mitral regurgitation (MR) is a rather common valvular heart disease. Therefore, lung cancer patients might benefit from a targeted therapy against specific IAPs. In conclusion, high expression of distinct IAPs significantly correlates with prognosis in lung cancer. Meta-analyses of clinicopathological variables revealed a significant association between survivin and T stage, UICC stage, the presence of lymph node metastasis, and grade of differentiation. Two studies that assessed the expression of XIAP and livin, respectively, proved a significant relationship of these IAPs with poor OS. Seven studies displayed a strong association between survivin and disease recurrence. The pooled hazard ratio (HR) of 33 studies that analyzed overall survival (OS) revealed a positive correlation between survivin expression and poor prognosis. Forty-five eligible studies with 4428 patients assessed the expression of the IAPs survivin, XIAP, livin, and BRUCE. We screened PubMed, Web of Science, and Scopus for studies that investigated the prognostic value and clinicopathological features of IAPs in lung cancer. The inhibitor of apoptosis proteins (IAPs) represent a heterogeneous family of anti-apoptotic proteins, some members of which have been reported to correlate with clinical outcome in lung cancer. Approximately 85% is non-small-cell and 15% is small-cell lung cancer. Lung cancer is the most common cause of cancer-related death worldwide.
0 kommentar(er)
